Evidence map›Paper›PMID 37401761›Full record

Trial reportGut microbes

Richard A Forsgård, Julia Rode, Karin Lobenius-Palmér, Annalena Kamm, Snehal Patil, Mirriam G J Tacken, Marleen A H Lentjes, Jakob Axelsson, Gianfranco Grompone, Scott Montgomery and 1 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Microbial metabolite oxindole curbs acute lung injury by suppressing CXCL13.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Microorganisms · 2024
    Article
  13. Article
  14. Review
  15. Article
  16. ProbioticFrontiers in cellular and infection microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Richard A ForsgårdNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID 0000-0002-1905-918X
Julia RodeNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID 0000-0001-9402-4756
Karin Lobenius-PalmérNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID 0000-0001-6061-4643
Annalena KammNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Snehal PatilClinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Mirriam G J TackenWageningen Bioveterinary Research, Wageningen University and Research, Lelystad, The Netherlands.
Marleen A H LentjesNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID 0000-0003-4713-907X
Jakob AxelssonBioGaia AB, Stockholm and Lund, Sweden.ORCID 0000-0003-4146-8374
Gianfranco GromponeBioGaia AB, Stockholm and Lund, Sweden.
Scott MontgomeryNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Robert J BrummerNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID 0000-0002-0362-0008
Örebro University · SEBioGaia (Sweden) · SEWageningen University & Research · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies have shown that probiotics can decrease the symptoms of respiratory tract infections as well as increase antibody responses following certain vaccinations. We examined the effect of probiotic supplementation on anti-SARS-CoV-2 specific antibody responses upon SARS-CoV-2 infection as well as after COVID-19 vaccination. In this randomized, triple-blinded, placebo-controlled intervention study with a parallel design, 159 healthy adults without prior SARS-CoV-2 infection or COVID-19 vaccination and any known risk factors for severe COVID-19 were randomly allocated into two study arms. The active treatment arm consumed a probiotic product containing a minimum of 1 × 10

Indexed as

COVID-19Gastrointestinal MicrobiomeLimosilactobacillus reuteriProbioticsAdultAntibodies, ViralAntibody FormationCholecalciferolCOVID-19 VaccinesHumansImmunoglobulin AImmunoglobulin GRNA, MessengerSARS-CoV-2Antibodies, ViralCholecalciferolCOVID-19 VaccinesImmunoglobulin AImmunoglobulin GRNA, MessengerantibodyCOVID-19immunologyProbioticsSARS-CoV-2

Identifiers

PMID37401761
PMCPMC10321188
OpenAlexW4383058821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.